– USA, CA – Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation platform technology to address gaps in cancer care, today announced the appointment of David Smith to its Board of Directors.
The company also announced the appointments of Elizabeth Smith and Dr. Richard Lopez (M.D.) to its Scientific Advisory Board.
“Following our recent Series C funding milestone, we are pleased to bring on a strong roster of industry leaders who bring deep expertise across allogeneic cell therapy development, regulatory affairs, and finance, to help us bring forth next-generation cell therapies for the people who need them most,” said CEO and co-founder, Dr. Sonny Hsiao.
About David V. Smith
Mr. Smith currently serves as a member of the Board of Directors at Codexis and Neurelis and most recently served as EVP and CFO of Five Prime Therapeutics, acquired by Amgen in 2021. Additionally, he served as COO at IntegenX. Previously in his career, he was EVP and CFO of Thoratec Corp., VP, and CFO at Chiron Corp., VP, and CFO of Anergen Inc., and held various financial management positions at Genentech, IBM, and Syntex Corp.
“I am honored to join such a strong board of directors and bring more than 30 years of financial and operational management experience across private and public companies to support the long-term growth and success of Acepodia,” said David Smith.
He received an MBA from Golden Gate University and a B.A. in Economics and History from Willamette University.
About Elizabeth Smith
Ms. Smith has more than 25 years of experience in providing regulatory guidance and strategy support, with a specialty in biologics, drugs, and cell and gene therapies. Ms. Smith currently serves as the Deputy Director of Regulatory Affairs at the Bill and Melinda Gates Foundation. Before this role, Ms. Smith held various roles at Juno Therapeutics, first as Senior Advisor to the CEO, then as SVP of Regulatory and Quality, where she spearheaded efforts to establish regulatory strategies for multiple genetically-engineered cell therapy assets. Following this role, Ms. Smith also served as Senior Strategic Advisor to the company’s development teams and the President of R&D. Before Juno Therapeutics, she served as VP of Regulatory Affairs at Dendreon and has held various regulatory positions at Genentech, where she began her career in manufacturing.
“I am thrilled to join the Acepodia Scientific Advisory Board and look forward to applying my expertise in regulatory affairs and strategy to support the company in advancing its revolutionary platform of cell therapies in both the development and commercial stages,” said Mais. Smith.
Ms. Smith graduated cum laude with a bachelor’s degree in biology from Central Washington University.
About Dr. Richard Lopez.
Dr. Lopez is a physician-scientist specializing in allogeneic cellular therapies and an expert in the area of gamma delta T cell cancer immunotherapies. Through his efforts in industry and medical practice, Dr. Lopez aims to improve the outcomes of patients affected by hematologic malignancies or solid tumors. He is the Founder and CEO of PhosphoGam, a biotechnology company working to revolutionize cancer cellular immunotherapy using off-the-shelf allogeneic human gamma delta T cells. He is also Associate Professor of Medicine at Duke University School of Medicine where he engages in extensive research in hematology. Dr. Lopez received an M.D. from Stanford University School of Medicine, where he also completed his medical residency and his fellowship in medical oncology and bone marrow transplantation.
“I am enthusiastic about the broad applicability of Acepodia’s technology platform and look forward to applying my passion and expertise in cell therapy development and hematology research to help Acepodia advance its mission to address gaps in cancer care using their unique cell therapy technology,” said Dr. Lopez.
About Acepodia
Acepodia is a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation platform technology to address gaps in cancer care. Leveraging its ACC technology, the company links tumor-targeting antibodies to its proprietary immune cells, such as gamma delta T cells and off-the-shelf natural killer cells to create novel antibody cell effector therapies, which have increased binding strength against tumors that express low levels of tumor antigens. Acepodia is made up of seasoned leadership and scientific experts dedicated to advancing its robust pipeline of off-the-shelf ACE therapies with the potential to bring innovative, effective, and affordable cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers.
For more information: https://www.acepodia.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
